Ben Hargreaves finds that a new line of attack could be the development of more effective non-opioid painkillers, with one potential therapy moving closer to approval. The opioid epidemic in the ...

On 30 January 2025, the US Food and Drug Administration (FDA) approved the non-opioid medication suzetrigine (JOURNAVX), which was developed by Vertex Pharmaceuticals for moderate to severe acute ...

The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

non-opioid pain medicine Journavx (suzetrigine). One of the organization's independent evidence appraisal committees split 7-7 in February that there is adequate evidence to demonstrate a net ...

Implementation of the ERAS program delivers better patient outcomes, achieves shorter lengths of stay, and saves money.

A trial of around 800 people with lower back pain suggested the cannabis-derived drug could be used as a painkiller ...

CHATHAM, NJ / ACCESS Newswire / March 31, 2025 /This post was written and published as a collaboration between the in-house ...

In particular, the NIH has emphasized efforts to develop non-opioid painkillers less likely to result in addiction. And in the past decade, advocacy groups representing chronic pain patients have ...

As a doctor of orthopedic physical therapy, I’ve treated numerous patients dealing with severe pain who were at risk for or already have opioid use disorder. This condition not only causes ...

A group of researchers from Weill Cornell Medicine and the Burke Neurological Institute has made an exciting breakthrough ...

A cannabis-derived drug is the first non-addictive and clinically-proven ... it can be used as an alternative for highly addictive opioid painkillers. The Munich-based company's chief executive ...